SightfileU.S. market data from official filings

Companies › GALT

GALECTIN THERAPEUTICS (GALT)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001133416 · EDGAR filings · Updated 2026-07-16

GALECTIN THERAPEUTICS (GALT) has reported institutional ownership of 21.1%, with 98 institutional managers holding positions valued at $38.6M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
21.1%
Institutional managers
98
Reported 13F value
$38.6M
Insider activity
140 trans.
−$6.61M net selling
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, GALECTIN THERAPEUTICS has 98 institutional holders and institutional ownership of 21.1%.

Insider activity

Insiders reported 140 transactions (8 buys, 65 sells) across 11 reporting insiders, with a net reported value of −$6.61M.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-15 (recurring since 2024-08-13) — source filing. The authoritative details are those stated in the filing itself.

Related companies

CARDIFF ONCOLOGY INC (CRDF) · CANTON STRATEGIC HOLDINGS IN (CNTN) · AUNA S A (AUNA) · AARDVARK THERAPEUTICS INC (AARD) · ACTUATE THERAPEUTICS INC (ACTU) · TENAYA THERAPEUTICS INC (TNYA)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-16.